Diabetes mellitus affects approximately 135 million people in the world. Diabetes and hypertension are both relatively common diseases in westernised countries. Both entities increase with age. Essential hypertension accounts for the majority of hypertension in people with type 2 diabetes, who constitute more than 90% of those with a dual diagnosis of diabetes and hypertension. The benefit conferred per mm Hg blood pressure reduction appears to be greater in persons with type 2 diabetes than in those with hypertension and non-coexistent diabetes mellitus. Similar to a subset of patients with essential hypertension, type 2 diabetic patients manifest dietary NaCl-induced exacerbation of hypertension. Recent guidelines have emphasised that the target blood pressure levels for patients with diabetes should be lower than in other hypertensive groups. An increased total body sodium and enhanced vascular
Introduction
Diabetes mellitus affects approximately 135 million people in the world and is projected to affect 300 million individuals by the year 2025. 1 Hypertension is twice as common in diabetics as in those who are not. 2 Conversely, available data suggests that persons with hypertension are much more likely to develop diabetes over a 5-year time interval. Taken together, these data suggest that both diseases have common underlying causes and coexistent risk factors. An estimated 35% to 75% of diabetic complications can be attributed to hypertension. About 90% of patients who have a dual diagnosis of diabetes and hypertension have type 2 diabetes. 2 Both entities increase with age and in individuals who are obese and/or lead a sedentary life.
There are substantial differences in the aetiology of hypertension in type 1 and type 2 diabetes mellitus. Type 1 diabetes mellitus is associated with hypertension only when albuminuria and early nephropathy develop. Essential hypertension accounts for the majority of hypertension in people with type 2 diabetes. 3 In type 1 diabetes, hypertension is seen in most of the 40% who develop nephropathy, but is observed no more frequently in those who escape nephropathy than in the non-diabetic population. 4 A strong family history of essential hypertension and diabetes mellitus appears to identify those people with type 1 diabetes who are most likely to develop renal disease and hypertension. 2 Probably an equal number of people with type 2 diabetes mellitus develop renal disease, but hypertension often occurs with normal renal function, associated with obesity and older age. The connection between hypertension, diabetes, and obesity is even stronger in those whose obesity is predominant in the upper body comprising the major components of the insulin-resistant syndrome.
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Mechanisms of hypertension in diabetes
Hypertension seen in type 2 diabetes is characterised by both volume expansion and increased peripheral resistance, the latter related to the accelerated atherosclerosis observed in this disease. In hypertension and in diabetes mellitus appears to exist a 'cardiometabolic syndrome' with insulin resistance and hyperinsulinaemia. In type 1 the amount of exogenous insulin given is larger than the normal endogenous levels; in type 2, because of the obesity-induced insulin resistance. Even though a causal relationship between insulin resistance and hypertension has not yet been established, hyperinsulinaemia and insulin resistance may contribute to hypertension in diabetes mellitus through effects on sodium retention, activation of sympathetic nervous system and direct effects on blood vessels. 6, 7 There is evidence that insulin resistance changes the intracellular electrolyte homeostasis. Hyperinsulinaemia induced by insulin resistance alters sodium pumps present on all human cell membranes. It causes an intracellular accumulation of sodium that sensitised the arteries to the pressor effects of angiotensin II and noradrenaline. 6, 8 In addition, the increase in activity of the Na + /H + exchanger causes an increase in the intracellular pH. Intracellular alkalinisation has been shown to stimulate protein synthesis and cell growth, which can lead to the hypertrophy of resistance vessels characteristic of established hypertension. 7 Similar to a subset of patients with essential hypertension, type 2 diabetes patients manifest dietary NaCl-induced exacerbation of hypertension. 8 Salt-sensitivity, defined as an increase in mean arterial pressure (MAP) of at least 10 mm Hg in response to high-salt dietary challenge or saline infusion, 9 has important clinical implications in diabetic patients with hypertension. These 'salt-sensitive' diabetic patients have a poor prognosis with respect to cardiovascular events. 10 There is a connection between salt-sensitive state and beta-cell dysfunction. It was recently reported that the salt-sensitive state is related to a reduced fall in blood pressure during the night in essential hypertension. 9 In essential hypertensives it was observed that the ratio of fasting insulin to glucose was higher in non-dippers. 11 The exact mechanism for the association between insulin resistance and salt-sensitivity is unclear. Increased intracellular Ca 2+ during sodium loading was described in saltsensitive subjects with essential hypertension. [12] [13] [14] [15] It was reported that the reduced insulin action (insulin resistance) was associated with high intracellular Ca 2+ due to the decreased activity of Ca
2+
ATPase and Na + , K + -ATPase, 14 which are both insulin sensitive. On the other side, dietary NaCl excess induces the activation of the sympathetic nervous system, which causes increased peripheral vascular resistance. Moreover, enhanced sympathetic nervous system activity may mediate the effect of insulin resistance (and associated hyperinsulinaemia) on vascular tone and arterial pressure. [15] [16] [17] In diabetes mellitus there is increased vascular reactivity to various vasoconstrictors and increased total exchangeable body sodium. These abnormalities are found in people with diabetes, both with and without hypertension or microvascular disease. Type 2 diabetes with hypertension is associated with reduced renal plasma flow when dietary salt intake is high. 17 Hyperglycaemia per se inhibits endothelium-derived relaxation, 16, 18 and its attend-
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ant volume expansion or perhaps metabolic perturbations may set the stage for sustained glomerular damage by inducing intraglomerular hypertension. This may be elicited by a hormonal agent or sympathetic nervous system activation that induce a decrease in afferent arteriolar resistance, which would in turn allows greater intraglomerular pressures and flows as a maladaptation to reduction in functional nephron mass. 19 Studies in animal models of diabetes mellitus have suggested that the metabolic disarray of the disease is associated with activation of the intrarenal renin system. 20 Price et al 21 have recently reported a combination of renal features that suggest independent angiotensinmediated control of the renal circulation in the majority of hypertensive patients with type 2 diabetes. These authors found in patients with a nonadvanced stage of diabetes when there is not yet an overt nephropathy, that despite a high salt intake, there was a blunted renal vasoconstrictor response to exogenous Ang II that is reflective of an increased Ang II operative on the kidney, and an exaggerated renal vasodilator response to angiotensin-converting enzyme (ACE) inhibitors, which was remarkable on a high salt diet. This triad is also a feature of one form of essential hypertension, non-modulation, [22] [23] [24] that is familial and is associated with a polymorphism in the angiotensinogen gene that could result in an excessive local Ang II effect. [23] [24] [25] Non-modulation is a disturbance defined as an increase in plasma aldosterone concentration of Ͻ15 ng/dl during the Ang II infusion (3 ng/kg/min for 45 min) while on a low salt diet. 25 Another controversial issue is whether or not patients with type 2 diabetes have a poorly suppressible renin release in response to a high salt diet. 26 When comparing renin-angiotensin-aldosterone system (RAAS) in hypertensive patients suffering from a non-late stage type 2 diabetes and essential hypertensives without diabetes, a higher incidence of low renin state was found in patients with essential hypertension. 21 Those authors observed an identical incidence of non-modulators in patients with essential hypertension or type 2 diabetes after exclusion of the low renin patients. Furthermore, the plasma renin activity (PRA) suppression in type 2 diabetic hypertensives was lower than in healthy subjects. Thus, in type 2 diabetic patients with hypertension the RAAS shows normal activation, but is poorly suppressible. The infrequency of a low renin state and the inappropriately high PRA on a high salt intake, provide a rational basis for pharmacologic interruption of the RAAS to treat patients with non-advanced stage of type 2 diabetes. Intraglomerular hypertension can be lowered by ACE inhibitors that maintain elevated renal blood flow. These agents induce an efferent arteriolar dilatation, thus providing an unique renoprotective effect. 27 The sustained renal haemodynamic responses to ACE inhibitors despite high-salt balance, and the inappropriate levels of PRA suggest 
Treatment strategies with respect to salt intake
Hypertensive patients with diabetes are commonly more resistant to treatment than non-diabetic patients with hypertension. Recent guidelines have emphasised that the target blood pressure levels for patients with diabetes should be lower than in other hypertensive groups. 28, 29 A systolic pressure of 130 to 139 mm Hg with a diastolic pressure of 85 to 89 mm Hg, classified as high normal, warrants prompt treatment in diabetic patients. Data from clinical trials indicate that office blood pressure at or below 130/85 mm Hg is a realistic goal for patients with diabetes. These recommendations are based on various studies interpreted to conclude that aggressive blood pressure reduction in this population is associated not only with a reduced rate of progression of renal disease but also a decreased incidence of cardiovascular events. Experimental, observational and interventional evidences support the benefits of sodium restriction in hypertension. As shown by Law et al, 30 the full effects of sodium restriction are usually not obvious for at least 5 weeks; yet many of the trials included in meta-analyses were for 10 to 14 days. The strongest data come from the Intersalt study, which measured 24-h urine electrolytes and blood pressure in 10 079 men and women aged 20 to 59 years in 52 places around the world. 31 For all 52 centres, there was a positive correlation between urinary sodium excretion and both systolic and diastolic blood pressure, but an even more significant association between sodium excretion and the changes in blood pressure with age. There is no evidence that lower levels of sodium intake, as achieved in intervention trials, present any safety hazards. The restriction of dietary salt intake might shift the circadian rhythm of blood pressure from a non-dipper to a dipper pattern as it was observed in non-diabetics with essential hypertension, resulting in amelioration of the risks. 32, 33 The American Heart Association Nutrition Committee stated that 'for the general population, the AHA recommends that the average daily consumption of NaCl by adults not exceed 6 g. There is no evidence that limiting NaCl consumption to 6 g per day poses any health risk'. 34 A recent study in older hypertensive patients showed no adverse effects of a reduction in sodium of 40 mmol (2.3 g) per day and after 18 months there was a significant reduction in the need for antihypertensive drug therapy. 35 
